Skip to content

14C-acetaminophen microdose clinical trial using AMS

14C-acetaminophen microdose clinical trial using AMS - 14C-acetaminophen microdose clinical trial using AMS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002084
Enrollment
12
Registered
2009-06-21
Start date
2009-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteer

Interventions

coadministration of acetaminophen and probenecid administration of acetaminophen alone

Sponsors

APDD
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: the investigors must ensure that all subjects being considerd meet the following inclusion criteria 1) capable to understand and sign the informed consent. 2) 20-45 years of age 3)BMI 18.5-25.0 4)good health as determined by physical examination, vital signs and laboartory tests.

Exclusion criteria

Exclusion criteria: the investigors must ensure that all subjects being considerd meet the following exclusion criteria or conditions 1)peptic ulcer 2)dysemia 3)kidney stone 4)history of cardiac disease 5)imparment of liver or kidney functions 6)any medical condition that reqires medical attention 7) recent (past 4 months) participation in other clinical trial and the investigator determines this trial participation inadequate 8)history of allergy to acetaminophen and probenecid 9)history of aspirin indeced asthma 10)donation of 400mL or more of blood within 3 months prior to participation, donation of 200mL or more of blood within 1 month prior to participation, or donation of component blood within 2 weeks prior to participation 11)positive serologic reaction of syphilis, positive result of HIV test, HBsAg and HCVAb 12)history of multiple and recurring allergies to medicines or food 13)history of drug or alcoholabuse 14) the investigator determines this trial participation inadequate

Design outcomes

Primary

MeasureTime frame
detection from radioactive concentraions of plasma, urin and feces samples.

Countries

Japan

Contacts

Public ContactTomoko Kobayashi

Medical Co.LTA Honjo Clinic Honjo Clinic

03-5608-7276

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026